The MA is characterized by recurrent episodes of transient focal neurologic dysfunction; visual aura is the most frequent symptoms, followed by sensory, aphasic, and motor auras [1].
This drug is generally well tolerated, although one of its most frequent adverse events is sensory peripheral neuropathy (PN).
Fokke et al. (2014) and Kalita and Misra (2014) reported that motor weakness was the most frequent symptom (73.8 100%) and sensory symptoms represented 52.7% and cranial nerve affection represented 53 62.5%.
The most frequent adverse events are transient sensory disturbances in the territory of the maxillary nerve (V2).
It is clinically defined by at least two recurrent episodes of fully reversible symptoms (the most frequent of which are visual disturbances, sensory disturbances and speech and/or language impairment).
Diabetic foot lesions develop predominantly in male patients and sensory neuropathy is the most frequent type of neuropathy associated with these lesions.
Peripheral sensory neuropathy was the most frequent grade 3/4 treatment-emergent adverse event (12 to 14%).
The most frequent presentation of distal symmetric polyneuropathy is distal sensory loss, while other symptoms include burning pain, paraesthesiae, hyperaesthesiae and deep aching pain.
Mechanical hyperalgesia without sensory loss (L0G2) was the most frequent coding in both OA and arthralgia patients diagnosed in accordance with each and combined examination modalities except for clinically diagnosed OA patients, where hypoesthesia to mechanical tactile stimuli along with mechanical hyperalgesia (L2G2) was the leading combination.
Human immunodeficiency virus (HIV -associated sensory neuropatHIV -associatedmosensoryueneuropathygical complication of HIV diSNase.
